SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation ADPT, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess minimal residual disease (MRD)…Read More
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ Assay Across BeiGenes Lymphoid Malignancy Pipeline Adaptive Biotechnologies NASDAQADPT
